Skip to main content

Table 1 Patient, lung cancer and treatment characteristics

From: Durvalumab after chemoradiotherapy for locally advanced non-small cell lung cancer prolonged distant metastasis-free survival, progression-free survival and overall survival in clinical practice

Category

Variables

68 patients (%)

Age, years

Median (range)

71 (43–84)

Sex

Female

13 (19.1)

Male

55 (80.8)

ECOG PS

0

37 (54.4)

1

27 (39.7)

2

4 (5.8)

Charlson comorbidity index

0

25 (36.7)

1

23 (33.8)

2

15 (22.0)

3–4

5 (7.3)

Smoking status

Never

9 (13.2)

Current

27 (39.7)

Former

32 (47.0)

Brinkman index

Median (range)

800 (0–1900)

FEV1 (L)

Median (range)

2.18 (1.12–3.67)

FEV1 (% of predicted)

Median (range)

88.0 (36.4–125.4)

FEV1/FVC (%)

Median (range)

71.6 (32.1–89.0)

Interstitial lung disease

No

65 (95.5)

Yes

3 (4.4)

Diabetes mellitus

No

56 (82.3)

Yes

12 (17.6)

COPD

No

48 (70.5)

Yes

20 (29.4)

Pathology

Adenocarcinoma

32 (47.0)

Squamous cell carcinoma

27(39.7)

Others

9 (13.2)

PD-L1 tumour proportion score

 < 1%

11 (16.2)

 ≥ 1%

31 (45.6)

Unknown

26 (38.2)

Stage (UICC 8th)

IIA-IIB

8 (11.7)

IIIA

23 (33.8)

IIIB

31 (45.5)

IIIC-IVA

6 (8.8)

Chemotherapy

No

18 (26.4)

Yes

50 (73.5)

 - Cisplatin/vinorelbine

24

 - Carboplatin/paclitaxel or nab-paclitaxel

20

 - Others

6

Total prescribed dose

60 (Gy)

56 (83.3)

66 (Gy)

10 (14.7)

Others

2 (2.9)

PTV (cc)

Median (range)

305.5 (77.6–958.9)

Radiation dose parameters

Dose coverage 90% of CTV (Gy)

60.9 (58.8–68.6)

Dose coverage 90% of PTV (Gy)

58.9 (55.5–66.0)

Median (range)

Lung V5 Gy (%)

56.2 (27.9–84.0)

Lung V20 Gy (%)

23.6 (11.1–35.1)

  1. ECOG Eastern Cooperative Oncology Group, PS performance status, FEC forced expiratory volume, FVC forced vital capacity, COPD chronic obstructive pulmonary disease, PD-L1 programmed death-ligand 1, PTV planning target volume, CTV clinical target volume, Lung Vn Gy percentage of total lung volume exceeding n Gy